The Steps Drug Makers Must Take Now To Avoid A Post-COVID-19 Manufacturing Crisis
Executive Summary
How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.
You may also be interested in...
FDA Prioritizes Shortages Post-Pandemic
Guidance from the FDA urges a focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches when the coronavirus pandemic recedes.
US FDA On Resuming Normal Manufacturing Operations When Pandemic Recedes
Focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches, agency guidance says.
Responding To FDA 483s And Warning Letters: Some Dos, Don’ts And Red Flags
Invalidated OOS results are ‘red flags’ during FDA inspections and ‘denying, delaying, limiting or refusing’ a drug inspection proposed by the agency could have serious consequence, participants at a recent webinar on best practices for responding to Form 483s and warnings letters heard.